SCHEMBL14373407

SCHEMBL14373407

CN(CCCn1c(=N)n(CC(=O)c2ccccc2)c2cccc(Cl)c21)C(=O)c1ccccc1

nearest known ligand 0.93

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CXCR3 P49682 19/20 0.93
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14373406 0.96 CXCR3 (1.00) CXCR3
SCHEMBL14470687 0.94 CXCR3 (0.86) CXCR3
SCHEMBL14373250 0.94 CXCR3 (0.86) CXCR3
Bromide SCHEMBL5094976 0.94 CXCR3 (0.85) CXCR3RAB9A
SCHEMBL14373845 0.93 CXCR3 (0.94) CXCR3
SCHEMBL14373414 0.92 CXCR3 (0.79) CXCR3NPC1RAB9A
SCHEMBL14373390 0.90 CXCR3 (0.89) CXCR3
SCHEMBL14373408 0.90 CXCR3 (0.82) CXCR3
SCHEMBL14373807 0.90 CXCR3 (0.88) CXCR3
SCHEMBL14373738 0.90 CXCR3 (0.87) CXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232673-A1 2-Imino-benzimidazoles ABBOTT LABORATORIES 2007-10-04 — — US disclosed
US-20070232673-A1 2-Imino-benzimidazoles ABBOTT LABORATORIES 2007-10-04 — — US disclosed
WO-2007084728-A2 2-IMINO-BENZIMIDAZOLES ABBOTT LABORATORIES (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232673-A1 2-Imino-benzimidazoles CYP2C19, UGT2B7, UGT2B17 CXCR3 4743/4885NPC1 234/4885RAB9A 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback